Skip to main content

Articles

PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes

Leukemia, Oncology

Ibrutinib: It’s Not Just for Leukemia

Ara-C Should Be Part of Conditioning Regimen in Young Patients with Mantle-Cell Lymphoma

Can Prognostic Factors Guide the Treatment of DLBCL?

Newly Discovered Genes in AML Can Identify Likely Response to Therapies

Leukemia, Oncology

Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib

NIH Research Funding Cuts Would Have Devastating Impact on Hematology

Leukemia, Oncology

Alternatives to “7 + 3” Induction Therapy for AML Are Emerging

Leukemia, Oncology

Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation

Leukemia, Oncology

“Dramatic” Responses with Targeted Agent for Patients with CLL

Page 183 of 244
Results 1821 - 1830 of 2434